Accelera Srl receives approval from the French Ministry of Research as a "Crédit d'Impôt Recherche" (C.I.R.) Certified Company

Nerviano (MI) Italy, August 3rd 2010 - Accelera Srl, a premium tier Contract Research Organization (CRO), working and collaborating with pharmaceutical and biotechnology companies around the world, announced today that the French Ministry of Research (FMR) has accepted the company's request to be included on the list of "FMR approved" CROs carrying out R&D activities for French private companies.

This approval by the FMR entitles any private French company to claim significant tax credits ("Crédit d'Impôt Recherche", C.I.R.) for R&D activities executed by Accelera on their behalf. Previously available through Accelera's parent company (Nerviano Medical Sciences, NMS), and valid for an initial two year period, approval by the FMR reflects Accelera's move to offer its service offering as a fully independent company.

Accelera already has a history of successful partnerships with a variety of French pharmaceutical and biotech companies, and believes that this new development, coupled with competitive pricing, should prove to be an attractive offering for companies in France looking to utilize Accelera's unique expertise and capabilities.

Further details on Crédit d'Impôt Recherche, and on procedures for obtaining tax credit for eligible companies, are available at:

http://www.enseignementsup-recherche.gouv.fr/cid20358/le-credit-d-impot-recherche-cir.html

For more information on Accelera, please visit www.accelera.org, or contact:

Michael J Prosser
Head, Business Development
Tel: +39 0331 1984 287, Fax: +39 0331 1984 200
Email: michael.prosser@accelera.org

About Accelera:
Accelera is a premium tier Contract Research Organization (CRO), working and collaborating with pharmaceutical and biotechnology companies around the world. Built on decades as part of the international pharmaceutical industry, Accelera can help predict and manage potential pharmacokinetic, metabolic, and toxicity issues, adding real value to your company's R&D programme. Services include:

- High-throughput preclinical profiling and in silico ADMET prediction and modeling;
- IND/CTA enabling packages, including GLP general toxicology, safety pharmacology, genotoxicity, ADME and pharmacokinetics (PK);
- Toxicology and ADME/PK studies in rodent and non-rodent species, including Nonhuman Primates (NHP);
- Bioanalysis and pharmacokinetics for preclinical and clinical studies, including assay development and validation, PK/PD, and population PK data analysis;
- Drug disposition packages, including the synthesis of radio-labeled compound and QWBA;
- Preclinical development consultancy and preparation of regulatory documentation.